Tango Therapeutics (United States)

Recent papers from Tango Therapeutics (United States)

1. Disruption of the CRL5 ubiquitin ligase complex enhances engineered T-cell persistence under chronic tumor antigen exposureCancer Immunology Research · 2026
2. Suppressing phosphatidylserine externalization overcomes cancer immune evasion and enhances immunotherapyMolecular Cancer Therapeutics · 2026
3. Genetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancerJournal of Biological Chemistry · 2026
4. TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy.Cancer Research · 2026
5. Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screensCell Reports Methods · 2026
6. The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP -Deleted CancersJournal of Medicinal Chemistry · 2026
7. The ABCD_BH034 antibody recognizes the phosphorylated 53BP1 peptide by ELISAAntibody Reports · 2026
8. Development of a Scalable Process for TNG348: A Potent, Selective, and Orally Bioavailable USP1 InhibitorOrganic Process Research & Development · 2026
9. TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancersCancer Discovery · 2026
10. Strengthening pandemic preparedness in Peru: a qualitative study of high-level leaders involved in the COVID-19 responseBMJ Public Health · 2026
11. Abstract 3090: VRK1 inhibition leverages paralog synthetic lethality to selectively target VRK2-deficient cancer cellsCancer Research · 2026
12. Abstract 6923: Targeting tumor-specific Tn-glycoforms of MUC1 and MUC4 with first-in-class antibody-drug conjugates: Preclinical efficacy and translational potential of GO-M100B and GO-M400Cancer Research · 2026
13. Abstract 2983: Genome-wide CRISPRi screen identifies RPS27 as a novel synthetic lethal target for TP53 mutant cancersCancer Research · 2026
14. Abstract 484: Hit finding and assay enablement for VRK1, a paralog synthetic lethal kinase target in VRK2-deficient cancers.Cancer Research · 2026
15. The Dibasics of M13 phage display: examining the substrate specificity of Escherichia coli outer membrane proteasesProtein Engineering Design and Selection · 2026
16. Subsequent Meningiomas Among Survivors of Childhood CancerJAMA Network Open · 2025
17. Recurrent Neural Networks Predict Future Peptide Aggregation for Drug DevelopmentMolecular Pharmaceutics · 2025
18. TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 ImmunotherapyCancer Research · 2025
19. Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens2025
20. MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor ModelsClinical Cancer Research · 2025